SEC Company Response from REGENERON PHARMACEUTICALS, INC. (REGN) (CIK 0000872589) (REGN) — May 22, 2007
REGENERON PHARMACEUTICALS, INC. (REGN) (CIK 0000872589)
Date: May 22, 2007 · CIK: 0000872589 · Accession: 0001341004-07-001671
AI Filing Summary & Sentiment
File numbers found in text: 000-19034
Referenced dates: May 10, 2007
Letter
Securities and Exchange Commission Division of Corporation Finance RE: Regeneron Pharmaceuticals, Inc. Form 10-K for the fiscal year ended December 31, 2006 File No. 000-19034
Dear Mr. Rosenberg:
We are in receipt of your letter dated May 10, 2007 to Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. regarding the above-referenced annual report on Form 10-K. We are in the process of finalizing a letter responding to your comments and will send it to you on or before May 31, 2007.
Sincerely,
/s/ Stuart Kolinski
Show Raw Text
CORRESP
1
filename1.htm
[Regeneron Pharmaceuticals, Inc. Letterhead]
May 22, 2007
BY EDGAR AND FACSIMILE
Mr. Jim B. Rosenberg
Senior Assistant Chief Accountant
Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 6010
100 F Street, NE
Washington, D.C. 20549
RE:
Regeneron Pharmaceuticals, Inc.
Form 10-K for the fiscal year ended December 31, 2006
File No. 000-19034
Dear Mr. Rosenberg:
We are in receipt of your letter dated May 10, 2007 to Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc. regarding the above-referenced annual report on Form 10-K. We are in the process of finalizing a letter responding to your comments and will send it to you on or before May 31, 2007.
Sincerely,
/s/ Stuart Kolinski
Stuart Kolinski
Senior Vice President & General Counsel